VALANX Biotech Appoints New Chief Scientific Officer
VALANX Biotech, a biotech company, has appointed Klaus Orlinger, PhD, as its new Chief Scientific Officer.
Klaus has over 15 years of industry experience in developing oncology and infectious disease drug candidates.
His appointment will drive the development of VALANX' GoldenSite platform to advance the development of best-in-class therapeutic protein conjugates.
This strategic hire bolsters the company's leadership team as it progresses its first antibody drug conjugate to candidate selection phase.
Author's summary: VALANX Biotech appoints Klaus Orlinger as CSO.